Dalroi:
As you know, I focus largely on the Janssen project and on 2331 et al. As time passes, I'll become more interested in anti-properdin.
Pretty simple issues for me.... GLIA has been working on it longer than others, and the company that can intervene in the activation of glial cells will, IMO, prosper.
At this market cap, I realize that one needs to see continued potential in the Adcons for near-term appreciation, but I don't follow them closely. I focus on putting together a basket of stocks with boom potential, not on riding imminent news. To answer your question...... no, I can't see anything wrong.
>> either this is again a golden opportunity or something is seriously wrong but i can find out <<
Don't know what to say..... this appears, to me, to be just like most of the other options expirations, except that it comes with high volume this time. |
